Related Experiment Video
Updated: Dec 26, 2025
05:41
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
3.3K
Therapies to modulate gut microbiota: Past, present and future
Akshita Gupta1, Srishti Saha2, Sahil Khanna3
1Department of Medicine, All India Institute of Medical Sciences, New Delhi 110029, India.
World Journal of Gastroenterology
|March 10, 2020
Summary
Fecal microbiota transplantation (FMT) effectively treats recurrent Clostridioides difficile infection (CDI). Standardized microbial replacement therapies offer an alternative, with potential for other diseases, but long-term safety requires more study.
Area of Science:
- Microbiome research
- Gastroenterology
- Infectious diseases
Background:
- The human gut microbiota plays a crucial role in health and disease.
- Disruptions in the gut microbial community are linked to various conditions, including antibiotic-associated diarrhea and Clostridioides difficile infection (CDI).
Purpose of the Study:
- To review the current understanding of microbial replacement therapies, particularly fecal microbiota transplantation (FMT).
- To explore the potential of these therapies for treating diseases beyond CDI.
Main Methods:
- Review of existing literature on fecal microbiota transplantation (FMT) and microbial replacement therapies.
- Discussion of current practices, standardization challenges, and safety data.
Main Results:
- Fecal microbiota transplantation (FMT) is a safe and effective treatment for recurrent CDI.
- Standardized microbial replacement therapies present an attractive alternative to current FMT protocols.
- Adverse effects of FMT are generally mild, but long-term safety data is limited.
Conclusions:
- Microbial replacement therapies hold significant promise for treating a range of diseases, including inflammatory bowel disease, irritable bowel syndrome, obesity, multidrug-resistant infections, and neuropsychiatric disorders.
- Further research and clinical trials are essential to establish the efficacy and long-term safety of FMT for non-CDI conditions.
- Current application of FMT for non-CDI conditions should be restricted to research settings.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
385
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
385
01:29Bacterial Flora of the Large Intestine
1.4K
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
1.4K
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
373
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
373
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
565
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
565
01:29Microorganisms in Medicine and Therapeutics
856
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
856
01:17Drugs for Treatment of Diarrhea-Predominant IBS
537
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
537